TY - JOUR T1 - Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01880-2018 VL - 53 IS - 1 SP - 1801880 AU - Karen M. Olsson AU - Katrin Meyer AU - Dominik Berliner AU - Marius M. Hoeper Y1 - 2019/01/01 UR - http://erj.ersjournals.com/content/53/1/1801880.abstract N2 - Portopulmonary hypertension (PoPH) and hepatopulmonary syndrome (HPS) are rare pulmonary vascular complications of portal hypertension [1]. In PoPH, pulmonary vascular resistance (PVR) is elevated, resulting in heightened right ventricular workload which may lead to right-sided heart failure. HPS is characterised by progressive hypoxaemia due to diffusion–perfusion mismatching caused by regional, mostly basilar, intrapulmonary vascular dilatations of capillary and pre-capillary vessels. The exact pathogenesis of both conditions is unclear, as is the underlying predisposition causing a small proportion of patients with liver disease to develop PoPH or HPS.Patients with portopulmonary hypertension may develop hepatopulmonary syndrome during treatment with pulmonary vasodilators http://ow.ly/brHB30mOIWn ER -